Insulin Glargine + Lixisenatide (Suliqua)
- Status:
- Grey - after consultant/specialist initiation
- Decision Date:
- October 2020
Comments
GREY specialist initiation and stabilisation of
dosage: restricted for those patients struggling to manage multiple injections.
Ongoing specialist support should be maintained for patients on this treatment.
Suliqua is available in two strengths:
- insulin glargine 100units/ml + Lixisenatide 50mcg/ml (Suliqua 10 - 40 pen)
- insulin glargine 100units/ml + Lixisenatide 33mcg/ml (Suliqua 30 - 60 pen)
Prescriber must ensure the correct strength and number of dose steps are stated on the prescription.
Grey Drug Classifications
- 8. Exceptionality where a small cohort of patients may benefit from prescribing can be identified
search again